[-] Show simple item record

dc.contributor.authorKachowski, Larisaeng
dc.contributor.authorOver, Darrell R.eng
dc.contributor.authorQiu, Kefengeng
dc.date.issued2012eng
dc.description.abstractFluoxetine (Prozac) and orlistat (Xenical) produce modest short-term weight loss, but their long-term benefits are unclear and their safety is uncertain. (Strength of Recommendation [SOR]: B, based on a meta-analysis of randomized controlled trials.) Topiramate (Topamax; immediate- and controlled-release formulations) can produce weight loss, but potential psychiatric and neurologic adverse effects limit its usefulness (SOR: B, based on randomized controlled trials.) Sibutramine (Meridia) produces weight loss but has been withdrawn from the U.S. market because of potential cardiovascular adverse effects.eng
dc.identifier.urihttp://hdl.handle.net/10355/13372eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2012 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network.eng
dc.relation.ispartofseriesAmerican family physician, 85, no. 06 (March 2012): 633-635.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subject.lcshInsulin resistanceeng
dc.subject.lcshWeight losseng
dc.subject.lcshDrugs -- Therapeutic useeng
dc.titleMedications for weight loss in patients with Type 2 diabetes mellituseng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record